{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:36:24Z","timestamp":1791905784798,"version":"4.3.4"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23-AI127935"],"award-info":[{"award-number":["K23-AI127935"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the current carbapenem-resistant organism crisis, conventional approaches to optimizing pharmacokinetic-pharmacodynamic parameters are frequently inadequate, and traditional salvage agents (eg, colistin, tigecycline, etc) confer high toxicity and\/or have low efficacy. However, several \u03b2-lactam agents with activity against carbapenem-resistant organisms were approved recently by the US Food and Drug Administration, and more are anticipated to be approved in the near future. The primary goal of this review is to assist infectious disease practitioners with preferentially selecting 1 agent over another when treating patients infected with a carbapenem-resistant organism. However, resistance to some of these antibiotics has already developed. Antibiotic stewardship programs can ensure that they are reserved for situations in which other options are lacking and are paramount for the survival of these agents.<\/jats:p>","DOI":"10.1093\/jpids\/piz002","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T04:28:37Z","timestamp":1548736117000},"page":"251-260","source":"Crossref","is-referenced-by-count":72,"title":["Defining the Role of Novel \u03b2-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms"],"prefix":"10.1093","volume":"8","author":[{"given":"Pranita D","family":"Tamma","sequence":"first","affiliation":[{"name":"Departments of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice J","family":"Hsu","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"2019101003060199800_CIT0001","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0002","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2019101003060199800_CIT0003","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.2015.12480","article-title":"Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012\u20132013","volume":"314","author":"Guh","year":"2015","journal-title":"JAMA"},{"key":"2019101003060199800_CIT0004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0005","doi-asserted-by":"crossref","first-page":"ofw090","DOI":"10.1093\/ofid\/ofw090","article-title":"Metallo-\u03b2-lactamase (MBL)-producing Enterobacteriaceae in United States children","volume":"3","author":"Logan","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2019101003060199800_CIT0006","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1128\/AAC.01275-10","article-title":"Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence","volume":"55","author":"Tsai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature13205","article-title":"Structure of the AcrAB-TolC multidrug efflux pump","volume":"509","author":"Du","year":"2014","journal-title":"Nature"},{"key":"2019101003060199800_CIT0008","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/JCM.03264-15","article-title":"Carbapenem-resistant non-glucose-fermenting Gram-negative bacilli: the missing piece to the puzzle","volume":"54","author":"Gniadek","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2019101003060199800_CIT0009","doi-asserted-by":"crossref","first-page":"e00472-17","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0010","doi-asserted-by":"crossref","first-page":"e02569-17","DOI":"10.1128\/AAC.02569-17","article-title":"In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM global surveillance program, 2012 to 2015","volume":"62","author":"Karlowsky","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14787210.2017.1268918","article-title":"The epidemiology of carbapenemases in Latin America and the Caribbean","volume":"15","author":"Escand\u00f3n-Vargas","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2019101003060199800_CIT0012","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fmicb.2015.00893","article-title":"Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options","volume":"6","author":"Chang","year":"2015","journal-title":"Front Microbiol"},{"key":"2019101003060199800_CIT0013","doi-asserted-by":"crossref","first-page":"e01140","DOI":"10.1128\/JCM.01140-18","volume":"56","author":"Tamma","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2019101003060199800_CIT0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.diagmicrobio.2017.07.013","article-title":"Review: molecular detection of extended spectrum-\u03b2-lactamase- and carbapenemase-producing Enterobacteriaceae in a clinical setting","volume":"89","author":"Rood","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0016","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1128\/AAC.03057-14","article-title":"Avibactam and class C \u03b2-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance","volume":"58","author":"Lahiri","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0017","doi-asserted-by":"crossref","first-page":"e01856-17","DOI":"10.1128\/AAC.01856-17","article-title":"Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0018","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0019","doi-asserted-by":"crossref","first-page":"e00414-18","DOI":"10.1128\/AAC.00414-18","article-title":"Aztreonam-avibactam combination restores susceptibility of aztreonam in dual-carbapenemase-producing Enterobacteriaceae","volume":"62","author":"Chew","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0020","doi-asserted-by":"crossref","first-page":"e00777-17","DOI":"10.1128\/AAC.00777-17","article-title":"Avibactam restores the susceptibility of clinical isolates of Stenotrophomonas maltophilia to aztreonam","volume":"61","author":"Mojica","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0021","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4137\/IDRT.S31567","article-title":"Trojan horse antibiotics\u2014a novel way to circumvent Gram-negative bacterial resistance?","volume":"9","author":"Tillotson","year":"2016","journal-title":"Infect Dis (Auckl)"},{"key":"2019101003060199800_CIT0023","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0024","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0025","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0026","doi-asserted-by":"crossref","first-page":"e01968-17","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0027","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019101003060199800_CIT0028","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1128\/AAC.00629-13","article-title":"Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa","volume":"57","author":"Tomaras","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijantimicag.2017.10.008","article-title":"Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model","volume":"51","author":"Ghazi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019101003060199800_CIT0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"2019101003060199800_CIT0031","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1128\/AAC.00163-15","article-title":"Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of \u03b2-lactamase-producing strains","volume":"59","author":"Castanheira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0032","doi-asserted-by":"crossref","first-page":"e02083-16","DOI":"10.1128\/AAC.02083-16","article-title":"Antimicrobial activity of ceftazidime-avibactam against Gram-negative bacteria isolated from patients hospitalized with pneumonia in U.S. Medical Centers, 2011 to 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0033","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diagmicrobio.2015.06.008","article-title":"Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014)","volume":"83","author":"Sader","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0034","doi-asserted-by":"crossref","first-page":"e02369-16","DOI":"10.1128\/AAC.02369-16","article-title":"Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying blaKPC collected in U.S. Hospitals from 2012 to 2015","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0035","doi-asserted-by":"crossref","first-page":"e02349-16","DOI":"10.1128\/AAC.02349-16","article-title":"Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States","volume":"61","author":"Satlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0036","doi-asserted-by":"crossref","first-page":"e00642-17","DOI":"10.1128\/AAC.00642-17","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0037","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/jac\/dkx066","article-title":"High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime\/avibactam in KPC-producing Klebsiella pneumoniae","volume":"72","author":"Shen","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0038","doi-asserted-by":"crossref","first-page":"e00537-17","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0039","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0040","doi-asserted-by":"crossref","first-page":"e02101-17","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0041","doi-asserted-by":"crossref","first-page":"e00408-18","DOI":"10.1128\/mSphere.00408-18","article-title":"Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype","volume":"3","author":"Castanheira","year":"2018","journal-title":"mSphere"},{"key":"2019101003060199800_CIT0042","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jac\/dky082","article-title":"In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime\/avibactam treatment","volume":"73","author":"Gaibani","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0043","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0044","doi-asserted-by":"crossref","first-page":"ofx101","DOI":"10.1093\/ofid\/ofx101","article-title":"Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature","volume":"4","author":"Shields","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2019101003060199800_CIT0045","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0046","doi-asserted-by":"crossref","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0047","doi-asserted-by":"crossref","unstructured":"Lomovskaya O , CastanheiraM, VazqueaJ, et al Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in Tango II (a Phase 3 study of the treatment of CRE infections) [Abstract 1874]. In: ID Week 2017, San Diego.","DOI":"10.1093\/ofid\/ofx163.1404"},{"key":"2019101003060199800_CIT0048","doi-asserted-by":"crossref","first-page":"e02534-16","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0049","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/AAC.00079-17","article-title":"In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","article-title":"In vitro activity of avibactam (NXL104) in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 \u03b2-lactamase-producing Klebsiella pneumoniae","volume":"39","author":"Akta\u015f","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2019101003060199800_CIT0051","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2019101003060199800_CIT0052","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-\u03b2-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0053","author":"Allergan"},{"key":"2019101003060199800_CIT0054","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0055","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2019101003060199800_CIT0056","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0057","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0058","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0059","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019101003060199800_CIT0060","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019101003060199800_CIT0061","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0062","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0063","doi-asserted-by":"crossref","first-page":"e01858-17","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane-tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0064","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2019101003060199800_CIT0065","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0066","doi-asserted-by":"crossref","first-page":"e01970-17","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0067","doi-asserted-by":"crossref","first-page":"ofy158","DOI":"10.1093\/ofid\/ofy158","article-title":"In vitro activity of ceftolozane\/tazobactam vs nonfermenting, Gram-negative cystic fibrosis isolates","volume":"5","author":"Forrester","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019101003060199800_CIT0068","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2015.04.012","article-title":"Microbiological activity of ceftolozane\/tazobactam, ceftazidime, meropenem, and piperacillin\/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis","volume":"83","author":"Kuti","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0069","doi-asserted-by":"crossref","first-page":"e02688-16","DOI":"10.1128\/AAC.02688-16","article-title":"In vitro activity of ceftolozane-tazobactam against multidrug-resistant nonfermenting Gram-negative bacilli isolated from patients with cystic fibrosis","volume":"61","author":"Grohs","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0070","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2018.05.002","article-title":"Ceftolozane\/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients","volume":"92","author":"Finklea","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0071","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jgar.2018.03.002","article-title":"In vitro antimicrobial activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis","volume":"14","author":"Gramegna","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2019101003060199800_CIT0072","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"2019101003060199800_CIT0073","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0074","author":"Merck"},{"key":"2019101003060199800_CIT0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2019101003060199800_CIT0076","unstructured":"Umeh O , CebrikD, FriedlandI, et al A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infections (cUTI). In: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010."},{"key":"2019101003060199800_CIT0077","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0078","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0079"},{"key":"2019101003060199800_CIT0080","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s10096-015-2375-0","article-title":"New promising \u03b2-lactamase inhibitors for clinical use","volume":"34","author":"Olsen","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019101003060199800_CIT0081","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"2019101003060199800_CIT0082","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1128\/AAC.00830-15","article-title":"Activity of imipenem with relebactam against Gram-negative pathogens from New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0083","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In vitro activity of MK-7655, a novel \u03b2-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0084","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0085","doi-asserted-by":"crossref","first-page":"e02209-16","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (results from the SMART Global Surveillance Program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0086","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","article-title":"Activity of imipenem-relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions\u2014SMART 2015\u20132016","volume":"15","author":"Karlowsky","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2019101003060199800_CIT0087","doi-asserted-by":"crossref","first-page":"e02406-17","DOI":"10.1128\/AAC.02406-17","article-title":"Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam","volume":"62","author":"Barnes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0088","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019101003060199800_CIT0089","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0090","unstructured":"Abstract 427. RESTORE-IMI 1: A multicenter, double-blind, comparator-controlled trial comparing the efficacy and safety of imipenem\/relebactam versus colistin plus imipenem in patients with imipenem-non-susceptible bacterial infections. In: 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21\u201324, 2018."},{"key":"2019101003060199800_CIT0091","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2019101003060199800_CIT0092","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"2019101003060199800_CIT0093","doi-asserted-by":"crossref","first-page":"e01904-17","DOI":"10.1128\/AAC.01904-17","article-title":"In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0094","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of meropenem combined with RPX7009, a novel \u03b2-lactamase inhibitor, against Gram-negative clinical isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0095","doi-asserted-by":"crossref","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0096","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0097","doi-asserted-by":"crossref","first-page":"e01694-17","DOI":"10.1128\/AAC.01694-17","article-title":"Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae","volume":"61","author":"Sun","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0098","doi-asserted-by":"crossref","first-page":"e01969-17","DOI":"10.1128\/AAC.01969-17","article-title":"Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model","volume":"62","author":"Sabet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0099","doi-asserted-by":"crossref","first-page":"e01551-18","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0100","article-title":"Ceftazidime\/avibactam, meropenem\/vaborbactam or both? Clinical and formulary considerations","author":"Pogue","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019101003060199800_CIT0101","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2019101003060199800_CIT0102","unstructured":"Facta Farmaceutici, S.p.A. Meropenem-vaborbactam package insert. Available at: http:\/\/www.vabomere.com\/media\/pdf\/vabomere-us-prescribing-information.pdf. Accessed January 28, 2019."},{"key":"2019101003060199800_CIT0103","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2019101003060199800_CIT0104","doi-asserted-by":"crossref","first-page":"e00449-17","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019101003060199800_CIT0105","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/8\/3\/251\/30125145\/piz002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/8\/3\/251\/30125145\/piz002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:30:54Z","timestamp":1694590254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/8\/3\/251\/5359452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":105,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,22]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piz002","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,2,22]]}}}